Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study
Background The MOVIE phase I/II trial (NCT03518606) evaluated the safety and antitumor activity of durvalumab and tremelimumab combined with metronomic oral vinorelbine in patients with advanced tumors. We present the results of the recurrent advanced cervical cancer cohort.Methods Patients received...
Saved in:
Main Authors: | Pernelle Lavaud, Esma Saada-Bouzid, Renaud Sabatier, Olivia Le Saux, Thibault de la Motte Rouge, Anthony Gonçalves, Elodie Coquan, Jean-Sébastien Frenel, Marta Jiménez, Alice Hervieu, Laurent Mathiot, François Legrand, Claire Cropet, Edith Borcoman, Emmanuelle Charafe |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/13/1/e010708.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
by: Chee Khoon Lee, PhD, et al.
Published: (2025-02-01) -
Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context
by: Abha A. Gupta, et al.
Published: (2025-01-01) -
The Fountainpen and the Metronome: Bloomsbury Dancing, or not
by: Caroline Marie
Published: (2005-12-01) -
Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer
by: Jiahao Zhang, et al.
Published: (2025-01-01) -
David Slays Goliath: Exceptional Efficacy of Oral Vinorelbine in Conquering Metastatic Finger Angiosarcoma
by: Te-Lin Hsu, et al.
Published: (2024-01-01)